Blood centers across the country are seeing a renewed interest in whole blood transfusions. The main fuel to this fire appears to be the recent change from AABB and the forthcoming 31st edition of Standards for Blood Banks and Transfusion Services which allows for the use of low titer group O whole blood in emergent situations for recipients of unknown blood type (AABB News, 2017).Read More
Dr. Clark is the Medical Director of Transfusion Medicine at the University of Tennessee Medical Center.
This is the first installment in what will be a regular series of questions and answers with blood industry thought leaders. This installment looks at Acrodose, an FDA-approved whole blood derived alternative to apheresis Single Donor Platelets.Read More
Radical change is coming to the hospital-blood center relationship. The cause will be a new guidance from the FDA requiring re-testing of platelets after 3 days of storage. The guidance is currently a draft, but industry insiders expect its release in final form this spring or summer.
For all its brutal cost in human suffering, the unfolding zika epidemic has provided a rich source of learning materials for the nation’s blood supply. In one sense, it is profoundly reassuring to the speed with which US regulatory agencies, pharmaceutical companies, and individual members of the blood supplier community have worked together to address an unfolding crisis.Read More